- Home
- PROK vs IGMS Comparison
PROK vs IGMS Comparison
Compare PROK & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- IGMS
- Stock Information
- Founded
- PROK 2015
- IGMS 1993
- Country
- PROK United States
- IGMS United States
- Employees
- PROK N/A
- IGMS N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- PROK Health Care
- IGMS Health Care
- Exchange
- PROK Nasdaq
- IGMS Nasdaq
- Market Cap
- PROK 85.5M
- IGMS 82.1M
- IPO Year
- PROK N/A
- IGMS 2019
- Fundamental
- Price
- PROK $0.58
- IGMS $1.32
- Analyst Decision
- PROK Hold
- IGMS Hold
- Analyst Count
- PROK 3
- IGMS 8
- Target Price
- PROK $3.50
- IGMS $6.00
- AVG Volume (30 Days)
- PROK 1.6M
- IGMS 955.4K
- Earning Date
- PROK 08-08-2025
- IGMS 08-13-2025
- Dividend Yield
- PROK N/A
- IGMS N/A
- EPS Growth
- PROK N/A
- IGMS N/A
- EPS
- PROK N/A
- IGMS N/A
- Revenue
- PROK $306,000.00
- IGMS $2,681,000.00
- Revenue This Year
- PROK $54.34
- IGMS $134.30
- Revenue Next Year
- PROK N/A
- IGMS $22.37
- P/E Ratio
- PROK N/A
- IGMS N/A
- Revenue Growth
- PROK N/A
- IGMS 27.36
- 52 Week Low
- PROK $0.46
- IGMS $0.92
- 52 Week High
- PROK $2.59
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- PROK 39.22
- IGMS 58.24
- Support Level
- PROK $0.54
- IGMS $1.12
- Resistance Level
- PROK $0.90
- IGMS $1.39
- Average True Range (ATR)
- PROK 0.13
- IGMS 0.08
- MACD
- PROK -0.03
- IGMS 0.01
- Stochastic Oscillator
- PROK 8.06
- IGMS 77.42
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.